• Our objective was to evaluate a 2014 cross-section of published systematic literature reviews (SLRs) in oncology and determine the top journals, meta-analysis frequency, main purposes and sponsorship.
1
-SLRs are increasingly favoured over traditional narrative reviews to objectively summarise vast amounts of data.
2
-Over the past 20 years, SLRs have shown continual publication growth. 1 • Not only are SLRs important for evidence dissemination in clinical practice, they are also becoming a prerequisite for grant funding and publication in some healthcare journals. 3, 4 • SLRs are used by regulatory stakeholders around the world.
-Findings from a recent US survey revealed that >80% of health plan directors use SLRs, and 53% regarded them as helpful towards their decision-making. 
Data Screening, Extraction and Synthesis
• Duplicates were removed using EndNote prior to level 1 (title/abstract) screening (n = 70).
• Studies were included if they met the following criteria:
-SLR or meta-analysis -Oncology focus -Description of drug therapy used in the treatment of cancer or in supportive care of patients receiving any type of treatment for cancer.
• Records not primarily about drug therapy in oncology were excluded.
• Records were reviewed to determine whether they were an SLR, meta-analysis or neither based upon title and abstract; data were then exported into Microsoft Excel for further analysis.
• The following information, where available in the study title or abstract, was extracted and classified: (Exhibit 2): -SLR only -SLR and meta-analysis -SLR research focus -Drugs studied -Country of publication -Open access of full text.
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• Full text was searched to identify and extract sponsorship/funding source if not reported in the abstract. 
Results
• A total of 1510 unique citations were identified; 727 were determined to be SLRs in oncology (Exhibit 3).
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• Of the 727 oncology SLR citations, 380 citations focused on drug therapy for oncology (Exhibit 4).
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• Journals publishing the largest number of SLRs were PLOS ONE (n = 29), Tumor Biology (n = 19), Cancer Treatment Reviews (n = 15), World Journal of Gastroenterology (n = 10) and Journal of Clinical Oncology (n = 8) ( Figure 1 ).
-Impact factors for these journals ranged from 2.369 to 18.428.
-PLOS ONE, Tumor Biology and Leukemia and Lymphoma journals published the most SLRs with meta-analyses (100%, 84.2% and 80% of total published SLRs, respectively) (Exhibit 5).
• The most common areas of research focus were treatment comparisons (28.6%), efficacy assessments (15.5%) and adverse event investigations (14.2%) (Figure 2 ).
• Of the targeted biologic therapies, vascular endothelial growth factor (VEGF) inhibitors and epidermal growth factor receptor (EGFR) inhibitors were among the highest reported (n = 20, 5.3% and n = 15, 3.9%, respectively) ( Figure 3 ).
-Bevacizumab (n = 14, 3.7%) and sorafenib (n = 11, 2.9%) were the leading cited products.
• Alkylating agents and antimetabolites were the most commonly reported classes of studied chemotherapy agent (n = 29, 7.6% and n = 22, 5.8%, respectively) ( Figure 3 ). • Sponsorship/funding was not reported in 39.2% of studies; in the remaining studies, authors described sponsorship/funding as independent (36.1%), none (15.5%) or industry (9.2%) (Figure 4 ).
-Independent funding was mainly provided by government (n = 64, 16.8%) and academic (n = 53, 14%) institutions.
• The majority of SLR lead authors were based in China (37.9%), the US (17.6%), Canada and Italy (7.4% each) ( Figure 5 ). Number of SLRs EGFR, Epidermal growth factor receptor inhibitor; HER2, Human epidermal growth factor inhibitor; mTOR, Mammalian target of rapamycin inhibitor; NS, not specified (specific agents/drug classes were not specified); VEGF, Vascular endothelial growth factor inhibitor. Other includes: studies in which therapies of focus did not fit into the specified categories (drugs for supportive care, prevention, supplements, etc.); Multiple includes: studies in several treatments/agents/classes were assessed.
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Study Limitations
• This assessment of SLRs was limited to oncology, and results may not be generalisable to other therapeutic areas.
• This analysis was restricted to a single year (2014); therefore, trend analysis was not feasible. • Searches were limited to publically available Embase and MEDLINE databases.
• Inclusion of meta-analysis, reasons for review, drug categories and country of origin were extracted from titles/abstracts; therefore, it is possible that some relevant data may have been excluded. • Manual review of full-text articles was conducted only for the purposes of obtaining information on sponsorship, and only when this was not available in the abstracts.
Please scan here to view a short clip of Sadiq Lula, SLR Consultant at Envision Market Access Solutions, discussing the top 5 mistakes people make when conducting SLRs
Conclusions
• In 2014 PLOS ONE published the most SLRs focusing on drug therapy in oncology.
• Journals offering open access are attracting a growing number of SLRs and many boast a diverse readership.
• The increasing requirement for SLRs in HTA submissions, coupled with a steady rise in the number of SLRs accepted for publication in recent years, indicates the growing importance of these reviews in evidence-based medicine.
• Despite Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines clearly stipulating that funding sources and other support should be disclosed in published SLRs, the majority did not report this information.
• Further analyses of the data are planned to assess transparency and level of compliance with PRISMA guidelines.
Results, continued Other, n = 10 (2.6%)
Independent: funding/sponsorship provided by non-industry; Industry: the study was funded/sponsored by pharmaceutical manufacturer; None: the publication explicitly stated that the authors reported no funding/sponsorship for the study; Not reported: the publication did not include any information regarding funding/sponsorship provided for the study; Other: hospital/multiple/private. 
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